Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Free Internet Access for Real-Time PCR Software Updates and Documentation

By BiotechDaily International staff writers
Posted on 27 Dec 2012
New technical information including software updates and documentation is now available free of charge over the Internet for a line of open chemistry real-time PCR systems.

Bibby Scientific (Staffordshire, United Kingdom) has announced that these materials for its Techne division's PrimeQ line of qPCR instruments can be downloaded from Techne's website.

The PrimeQ real-time PCR system has been designed with an open architecture and chemistry format that allows user flexibility in qPCR methods and research pursuits. The supporting Quansoft software provides an easy to use comprehensive data analysis package with the flexibility to edit experiment setup even after the run is complete. The open chemistry format, use of universal consumables, and large variety of excitation and emission filters allows users maximum flexibility while minimizing costs.

The new technical and application notes available for download cover topics ranging from the principle of absolute quantification analysis and high resolution melting through to minimizing sample volumes and an analysis of different manufacturers’ consumable kits.

Jim Bratherton, Techne product manager at Bibby Scientific said, “PrimeQ is an economical investment for three reasons. Firstly, our policy to provide free software licenses and upgrades for life; secondly, the 96-well format of PrimeQ allows the use of almost any low-profile qPCR plates; and thirdly, the open chemistry format of PrimeQ provides the ability to use most manufacturer’s reagent kits.”

Related Links:

Bibby Scientific
Techne



Channels

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.